A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Completed · Phase 2 · NCT04309474
Conditions: Acute Ischemic Stroke
At a glance
- Research payments reported, 2025
- $192,130
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 121
About the trial
- Sponsor
- AbbVie
- Tested
- Elezanumab (drug), Placebo (drug)
- Dates
- Started 2020-11-09; completion 2024-12-23
- Results posted
- Yes
Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess change in neurologic function in participants following an acute ischemic stroke. Elezanumab is an investigational drug being developed for the treatment of acute ischemic stroke. This 52-week study is "double-blinded', which means that neither the participants nor the study doctors will know who will be given elezanumab and who will be given placebo (does not contain treatment drug). Participants will be assigned…
From ClinicalTrials.gov, last updated 2025-12-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $192,130 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- William K. Freeman, M.D. Cardiology · Scottsdale, AZ
- Cumara M. O'carroll, M.D. Neurology · Scottsdale, AZ
- Nima Ramezan Arab, M.D. Neurology · Los Alamitos, CA
- Martin S. Gizzi, MD Neurology · Torrington, CT
- Wei Liu Neurology · Louisville, KY
- Matthew A. Edwardson, MD Neurology · Bethesda, MD
- Andrew N. Russman, D.O. Neurology · Detroit, MI
- Andria L. Ford, MD Neurology · Saint Louis, MO
- Yousef Hannawi, MD Neurology · Columbus, OH
- Elan Miller Neurology · Philadelphia, PA
- Andrew M. Southerland, M.D. Neurology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Virginia Medical Center, VA $63,632
- Hackensack University Medical Center, NJ $41,525
- Georgetown University $40,385
- Cleveland Clinic, OH $13,698
- The Ohio State University $10,338
- University of Louisville Research Foundation $5,314
- Washington University $5,020
- Thomas Jefferson University $4,207
- Memorial Health Services $3,662
- Mayo Clinic Florida $3,050
- Mayo Clinic Hospital, AZ $1,300
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.